REGENXBIO doses first patient in Phase IIb/III DR trial; earns $100M milestone from AbbVie

REGENXBIO Inc.

First patient dosed in Phase IIb/III NAAVIGATE trial of sura-vec for diabetic retinopathy using suprachoroidal delivery.
Triggered $100M milestone payment from AbbVie, expected in July 2026.
Phase IIb portion to enroll ~135 patients in U.S.; primary endpoint is ≥2-step DRSS improvement at one year.
To present 2.5-year ALTITUDE and 5-year subretinal data at ASRS July 2026.
Topline data from ATMOSPHERE and ASCENT pivotal trials expected Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.